• Home
  • Overview
    • Results of the early benefit assessment
      • G-BA procedures
      • Resolutions
      • Subpopulations
      • Patients
    • Indication areas (G-BA)
      • Eye diseases
      • Skin diseases
      • Cardiovascular diseases
      • Infectious diseases
      • Respiratory system diseases
      • Hematopoietic diseases
      • Musculoskeletal system diseaeses
      • Nervous system diseases
      • Genitourinary system diseases
      • Digestive system diseases
      • Oncological diseases
      • Mental illnesses
      • Other diseases
      • Metabolic diseases
      • Orphan Drugs
    • Special constellations
      • Orphan drugs
      • ATMP
      • ATMP CAR-T cells
      • PUMA
      • Evidence transfer
      • Reserve antibiotics
      • Conditional marketing authorisation
      • Approval under exceptional circumstances
      • Accelerated assessment
      • New data protection
      • Procedures without a dossier
    • Results of reassessments
      • Limitation
      • G-BA request (§13 VerfO)
      • Manufacturer's request (§14 VerfO)
      • Orphan drugs, exceeding turnover limit
      • Orphan drugs, loss of status
    • G-BA requirements
      • Accompanying data collection (AbD)
      • Quality requirements for ATMP
      • Bundling
      • Repealed resolutions
  • Procedures
    • G-BA resolutions
    • G-BA active procedures
    • G-BA procedures not completed
    • EMA CHMP positive opinions
  • Reimbursement prices
    • Recent price changes
    • Arbitration results
    • Discontinuations
    • Special practice conditions
    • AM-RL Appendix III: Prescription exclusions
    • AM-RL Appendix VI: Off-label Use
    • AM-RL Appendix VIIa: Biosimilars
    • AM-RL Appendix XIIa: Combination discounts
  • Interactive Analysis
    • Resolutions
    • Subpopulations
    • All Procedures (active+resolutions)
  • Intelligent search
  • EU-HTA-Monitor
  • Fundamentals
    • AMNOG Monitor step by step
      • Detailed analysis for each G-BA resolution
      • Interactive analysis
      • Interactive analysis: Excel export
      • Interactive analysis: Bookmarks
      • Interactive analysis: dimensions
      • Intelligent search
      • Monthly report
      • AMNOG Monitor app
      • Calculation methods
    • EMA regulatory procedure
    • Changes in legal regulations
    • Technical terms English-German
  • Contact
    • Contact form
    • Legal notice
    • Privacy policy
Logo AMNOG-Monitor.com
Search G-BA resolutions

In case you forgot your password ...

If you forgot your password, please enter your email address. We will contact you and explain the steps needed to obtain a new password.

Reset Password

Return to login form

  • Deutsch
  • English
  • Limitation
  • G-BA request (§13 VerfO)
  • Manufacturer's request (§14 VerfO)
  • Orphan drugs, exceeding turnover limit
  • Orphan drugs, loss of status

Forgot your password?

If you do not remember your password anymore, enter your email address below. We will contact you and explain the steps needed to obtain a new password.

Reset Password

Return to login form

AMNOG-Monitor > Overview > Results of reassessmentsLimitation

AMNOG monitor · Institut für Pharmakologie und präventive Medizin (IPPMED) Dr. Bramlage & Dr. Hankowitz Partnerschaft · www.ippmed.de